Stock Ratings / Health Care / CBLL / options

CNMD (62) INMD (74) TMDX (69) AXGN (54) ⌘ Pro Terminal →

CeriBell Inc. (CBLL) Options Positioning, Max Pain & Unusual Sweeps

$27.82 +2.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

CeriBell Inc. (CBLL) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.07B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CBLL)Realized 20D OHLCV Swing Band: ±11.9%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±11.9%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CBLL)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CBLL.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CBLL)

✓Walkthrough of CBLL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CBLL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.00%📐 HORIZONTAL RANGE

2026-10-30O $27.48H $27.82L $26.01C $27.82VOL 582.7K

RES: $30.54SUP: $22.43SMA50: $24.92SMA200: $20.78

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CBLL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CBLL Butterfly Map → + Track CBLL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +36.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CBLL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CBLL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CBLL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CBLL)

Health Care Rank #475 of 1016 ⚔️ CNMD vs CBLL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CBLL vs. CNMD, INMD, TMDX, AXGN)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CeriBell Inc. (CBLL) ranks #475 by composite RQD confidence (45/100, grade D) and #357 by equity capitalization ($1.07B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. INMD currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with CBLL at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CBLL ACTIVE CeriBell Inc.	D	45/100	—	87.9%	-35.0%	+2.20%	$1.07B	Benchmark Subject
CNMD CONMED Corporation	C	62/100	28.9x	54.6%	7.8%	-0.09%	$1.36B	/cnmd-vs-cbll →
INMD InMode Ltd.	B	74/100	—	78.5%	17.7%	+1.05%	$776.6M	/inmd-vs-cbll →
TMDX TransMedics Group Inc.	C+	69/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	/tmdx-vs-cbll →
AXGN Axogen Inc.	D+	54/100	—	74.3%	-2.6%	+0.77%	$2.96B	/axgn-vs-cbll →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001861107

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CeriBell Inc. (CBLL) reported GAAP revenue of $89.1M (+36.1% vs. FY2024 revenue of $65.4M , and +96.9% cumulative change since FY2023) , GAAP net income of -$53.4M, operating cash flow of -$40.8M, and free cash flow of -$41.6M (-14.3% YoY). On the balance sheet, CBLL closed FY2025 with $195.8M in total assets against $0 in total debt (Altman Z-Score: 14.75, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$89.1M	-$53.4M	-$40.8M	-$41.6M	$195.8M	—
FY2024 (FY)	2024-12-31	$65.4M	-$40.5M	-$35.0M	-$36.4M	$225.4M	—
FY2023 (FY)	2023-12-31	$45.2M	-$29.5M	-$29.2M	-$29.2M	—	—

3. CBLL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CBLL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CeriBell Inc. (NASDAQ: CBLL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $27.82 (+2.20% 1D, market cap $1.07B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CBLL ranks #475 in composite RQD confidence.

How does CBLL compare to CNMD and INMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CBLL carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 87.9%, and ROIC of -35.0%. By comparison, CNMD (CONMED Corporation) holds a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B) and INMD (InMode Ltd.) posts a B grade (74/100 RQD, P/E N/A, ROIC 17.7%, cap $776.6M). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CBLL?

Per CBLL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861107), CeriBell Inc. generated $89.1M in revenue (+36.1% YoY), -$53.4M in net income, and -$41.6M in free cash flow against $195.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CBLL trading relative to its 50-day, 200-day, and 52-week technical levels?

CBLL last traded at $27.82 (+2.20% on volume of 405,322 shares), positioning the stock +11.64% above its 50-day simple moving average ($24.92) and +33.88% above its 200-day simple moving average ($20.78). Across its 52-week range of $10.85 to $28.19, CBLL sits at the 97.9% percentile with a 14-day RSI of 54.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($24.51 to $31.13).

CBLL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CBLL's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CBLL.

Direct Sub-Reports: CBLL RQD Cockpit CBLL 12M Forecast CBLL Earnings & Move CBLL Dividends & DRIP CBLL Insiders & 13F CBLL Whale Options CBLL Profit Sankey CBLL News & Why